We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+0.8%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.76B
AUM Growth
-$301M
(-6%)
Cap. Flow
-$879M
Cap. Flow
% of AUM
-18.47%
Top 10 Holdings %
Top 10 Hldgs %
31.51%
Holding
169
New
40
Increased
23
Reduced
18
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$128M |
| 2 |
Boston Scientific
BSX
|
+$108M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$89.6M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$76M |
| 5 |
The Oncology Institute
TOI
|
+$53.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nkarta
NKTX
|
+$87.3M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$69.3M |
| 3 |
OSH
Oak Street Health, Inc.
OSH
|
+$58.2M |
| 4 |
DFPHU
DFP Healthcare Acquisitions Corp. Unit
DFPHU
|
+$56.1M |
| 5 |
DFHTU
Deerfield Healthcare Technology Acquisitions Corp. Unit
DFHTU
|
+$50.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.89% |
| 2 | Consumer Discretionary | 0.23% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Viatris
VTRS
$20.1B
| $241M | 5.06% |
17,224,000
+1,500,000
| +10% | +$24.4M |
|
|
2
Edgewise Therapeutics
EWTX
$4.28B
| $128M | 2.69% |
+3,933,137
| New | +$128M |
|
3
Centene
CNC
$32.8B
| $127M | 2.67% |
1,985,619
-444,381
| -18% | -$27.5M |
|
|
4
Boston Scientific
BSX
$65.4B
| $110M | 2.32% |
+2,857,000
| New | +$108M |
|
|
5
The Oncology Institute
TOI
$535M
| $104M | 2.19% |
10,460,000
+5,000,000
| +92% | +$53.3M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $88.6M | 1.86% |
+579,248
| New | +$89.6M |
|
7
Biogen
BIIB
$30.4B
| $86.7M | 1.82% |
310,000
-138,000
| -31% | -$37.2M |
|
8
AdaptHealth
AHCO
$1.49B
| $83.7M | 1.76% |
2,277,871
+471,539
| +26% | +$16.7M |
|
|
CMAX
9
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $82.2M | 1.73% |
225,958
+112,000
| +98% | +$47.3M |
|
10
Pacira BioSciences
PCRX
$1.01B
| $81.7M | 1.72% |
1,164,973
+115,326
| +11% | +$8.24M |
|
11
Larimar Therapeutics
LRMR
$384M
| $75.2M | 1.58% |
5,144,539
| – | – |
|
|
12
Neurocrine Biosciences
NBIX
$17.2B
| $70.5M | 1.48% |
+725,000
| New | +$76M |
|
13
Mirum Pharmaceuticals
MIRM
$7.25B
| $68.4M | 1.44% |
3,448,912
| – | – |
|
14
Revolution Medicines
RVMD
$39.6B
| $65.9M | 1.39% |
1,436,712
+40,329
| +3% | +$1.81M |
|
15
Cytokinetics
CYTK
$10.9B
| $59.6M | 1.25% |
2,561,000
+100,000
| +4% | +$2.14M |
|
|
ACH
16
Accendra Health
ACH
$266M
| $58.2M | 1.22% |
1,549,000
+453,000
| +41% | +$14.2M |
|
|
AFIB
17
DELISTED
Acutus Medical Inc
AFIB
| $58M | 1.22% |
4,341,799
| – | – |
|
18
Zimmer Biomet
ZBH
$17.6B
| $57.1M | 1.2% |
367,710
+269,860
| +276% | +$41.8M |
|
19
Organogenesis Holdings
ORGO
$337M
| $54.6M | 1.15% |
+2,995,638
| New | +$40.6M |
|
20
Molina Healthcare
MOH
$11.7B
| $54.2M | 1.14% |
231,776
+106,776
| +85% | +$23.8M |
|
|
TERN
21
DELISTED
Terns Pharmaceuticals
TERN
| $51.6M | 1.08% |
+2,345,959
| New | +$51.4M |
|
22
Alphatec Holdings
ATEC
$1.31B
| $50.6M | 1.06% |
3,201,916
+1,201,916
| +60% | +$18.9M |
|
|
ORTX
23
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $50.5M | 1.06% |
694,942
| – | – |
|
|
OCDX
24
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
| $45.4M | 0.95% |
+2,352,941
| New | +$41.5M |
|
25
Brookdale Senior Living
BKD
$3.58B
| $45.3M | 0.95% |
7,490,845
-3,532,620
| -32% | -$19M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q1 2021 Portfolio in Review
As of Q1 2021, Deerfield Management held 169 positions worth $4.76B, down 6% from $5.06B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Deerfield Management withdrew a net $879M in Q1 2021, closing 45 positions and reducing 18 holdings. Its most notable exit was Nkarta, an estimated $87.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 70% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Deerfield Management opened a new position in Edgewise Therapeutics worth $128M.
- Deerfield Management's largest Q1 2021 buy was Edgewise Therapeutics: 3,933,137 shares worth $128M.
- Deerfield Management added most to The Oncology Institute in Q1 2021, an estimated $53.3M increase.
- Deerfield Management's biggest Q1 2021 reduction was SpringWorks Therapeutics, cutting an estimated $69.3M.
- Deerfield Management fully exited Nkarta in Q1 2021, selling an estimated $87.3M.
- Deerfield Management's ten largest holdings make up 32% of its $4.76B portfolio in Q1 2021.
- Deerfield Management opened 40 new positions and closed 45 in Q1 2021.
- Deerfield Management's portfolio value fell 6% quarter-over-quarter to $4.76B.
Based on Deerfield Management's 13F filing for Q1 2021, filed 17 May 2021.